SCHEMBL7175144

SCHEMBL7175144

CS(=O)(=O)c1ccc(-c2cccnc2-c2ccccn2)cc1

nearest known ligand 0.74

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 16/20 0.74
PTGS1 P23219 5/20 0.74
TGFBR1 P36897 1/20 0.52
DRD1 P21728 1/20 0.47
SCD O00767 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28147345 0.88 PTGS2 (0.74) PTGS2PTGS1TGFBR1SCD
SCHEMBL8442044 0.85 PTGS2 (1.00) PTGS2PTGS1
SCHEMBL8229590 0.82 PTGS2 (0.64) PTGS2PTGS1TGFBR1SCD
SCHEMBL4889545 0.81 PTGS2 (1.00) PTGS2PTGS1TGFBR1
SCHEMBL8483738 0.81 PTGS2 (0.81) PTGS2PTGS1
SCHEMBL28146262 0.79 PTGS2 (0.69) PTGS2PTGS1
SCHEMBL8483933 0.79 PTGS2 (0.78) PTGS2PTGS1
SCHEMBL57318 0.79 KDM4E (0.50) PTGS2PTGS1TGFBR1
SCHEMBL8621133 0.79 PTGS2 (0.47) PTGS2PTGS1
SCHEMBL790509 0.78 PTGS2 (0.75) PTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2582690-B1 PROCESS FOR PREPARATION OF 2, 3-DIARYL-5-SUBSTITUTED PYRIDINES AND THEIR INTERMEDIATES GLENMARK GENERICS LTD (IN) 2018-07-25 EP disclosed
EP-2582690-A1 PROCESS FOR PREPARATION OF 2, 3-DIARYL-5-SUBSTITUTED PYRIDINES AND THEIR INTERMEDIATES Glenmark Generics Limited (IN) 2013-04-24 EP disclosed
WO-2011158250-A1 PROCESS FOR PREPARATION OF 2, 3-DIARYL-5-SUBSTITUTED PYRIDINES AND THEIR INTERMEDIATES GLENMARK GENERICS LIMITED (IN) 2011-12-22 WO disclosed
EP-1282423-A2 PREVENTION OF INSULIN-DEPENDENT DIABETES, COMPLICATIONS THEREOF, OR ALLOGRAFT REJECTION BY INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY WITH NS398 OR PDTC Oklahoma Medical Research Foundation (US) 2003-02-12 EP disclosed
US-20030017148-A1 Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity OKLAHOMA MEDICAL RESEARCH FOUNDATION 2003-01-23 US disclosed
WO-2001085175-A2 PREVENTION OF INSULIN-DEPENDENT DIABETES, COMPLICATIONS THEREOF, OR ALLOGRAFT REJECTION BY INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY WITH NS398 OR PDTC OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 2001-11-15 WO disclosed